Infosys Board Recommends Capital Return Of $2.08 Bln, Including Dividend And Share Buyback

Infosys Ltd (INFY) said that its board has recommended capital return of 15,600 crore Indian rupees or about $2.08 billion including final dividend of 6,400 crore rupees or about $0.85 billion and open market buyback of shares of 9,200 crore rupees or about $1.23 billion.

Looking ahead for fiscal year 2022, the company expects operating margin to be 22%-24%, and revenue growth of 12%-14% in constant currency.

The board approved buyback of equity shares amounting to 9,200 crore rupees at a price not exceeding 1,750 rupees per share or $23.3 per ADS.

The board has recommended a final dividend of 15 rupees per share or $0.20 per ADS. Together with the interim dividend of 12 rupees per share already paid, the total dividend per share for fiscal year 2021 will amount to 27 rupees per share or $0.36 per ADS which is a 54% increase over fiscal year 2020.

Infosys reportedly said it will hire 26,000 people from India and overseas in fiscal year 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The 737 MAX 10, Boeing Co.'s largest 737 Max model, is taking its maiden flight today, reports said citing people familiar with the matter. The flight after months of testing and certification will be around 10 a.m. local time from the Seattle area. The schedule could change depending on weather or other factors. Meanwhile, the jetliner is expected to enter commercial service in 2023. Medical devices supplier Smiths Medical, affiliated to Smiths Group plc, is recalling certain Jelco Hypodermic Needle-Pro Fixed Needle insulin syringes with skewed graduation markings, the U.S. Food and Drug Administration said. The recall was initiated after the company became aware of specific models and lots of Jelco insulin syringes that may exhibit skewed odd number line graduation markings. Saliva-based COVID-19 testing is rolled out as a pilot for public schools in New York City. The new two-month pilot program is being implemented in about 50 New York City public schools and utilizes Fluidigm Technology to offer RT-PCR COVID-19 testing. New York City public schools have instituted mandatory random weekly testing in all reopened school buildings to ensure safer in-person learning.
Follow RTT